All In MedTech

Device Trial Radar · NCT07216885

Solv Multi-Pass Hemodialysis System In-Center Clinical Study

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

4

Actual

Start

Jan 13, 2026

Primary completion

Sep 11, 2026

Study completion Sep 11, 2026

Sponsor

Lead sponsor
Mozarc Medical US LLCNot on our public-company list
Sponsor type
Industry
First posted
Oct 15, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Solv In-Center clinical study is a pre-market, prospective, multicenter, single arm, open-label clinical study. The patient population will include patients with kidney failure or insufficiency requiring hemodialysis and/or ultrafiltration. Eligibility will be open to incident dialysis patients and patients currently receiving HD in an in-center environment. All vascular access types including AV-fistula, AV-graft, and tunneled hemodialysis catheters.

Conditions

  • End Stage Renal Disease

Interventions

  • Solv Multi-Pass Hemodialysis SystemDevice

    Solv Multi-Pass Hemodialysis System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety EndpointTime frame: through study completion, an average of 1 year

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Carolina Nephrology

    Greenville, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.